Klotho Minicircle Gene Therapy

Abstract

Klotho is a longevity-associated protein primarily produced in the kidneys and known to regulate aging-related pathways including phosphate metabolism, oxidative stress resistance, and neuronal function. Circulating Klotho levels decline significantly with age and correlate with cognitive decline, kidney dysfunction, and increased all-cause mortality.

We report preliminary observations from a minicircle-based gene therapy approach designed to transiently increase systemic Klotho levels through subcutaneous adipocyte transfection.

Initial clinical observations suggest:

• Rapid elevation of circulating Klotho levels, confirmed by plasma ELISA
• Improvements in mild age-related cognitive complaints in patients over 55
• Improvements in renal function markers, including eGFR, in patients with impaired kidney function
• Sustained biological activity for approximately 8–12 months per administration
• Favorable PSA trends in male patients across multiple cases

Further longitudinal data collection is ongoing. This report has been updated in June 2026 to incorporate new supporting evidence from the peer-reviewed literature and to reflect current monitoring protocols.

Background

The Klotho protein has emerged as one of the most significant molecular regulators of aging. Discovered in 1997 by Dr. Makoto Kuro-o, Klotho-deficient mice exhibit accelerated aging phenotypes including cognitive decline, vascular calcification, osteoporosis, and shortened lifespan. Conversely, Klotho overexpression extends lifespan by 30–40% in full-length transgenic models.

Klotho acts as a regulator of phosphate metabolism, an inhibitor of insulin/IGF-1 and Wnt signaling, a neuroprotective factor, a renal protective protein, and a suppressor of oxidative stress and chronic inflammation. Circulating Klotho levels decline significantly from the 40s onward, making it one of the most compelling therapeutic targets in longevity medicine.

Why Minicircle Rather Than AAV?

The peer-reviewed literature on Klotho gene therapy has predominantly used adeno-associated virus (AAV) vectors for gene delivery. The Roig-Soriano et al. 2025 study, for example, used an AAV9 serotype vector. AAV delivery achieves high transduction efficiency and has been the dominant platform in formal clinical trial programs.

Our clinical approach uses minicircle DNA vectors for several reasons grounded in the specific goals of a non-integrating, transient longevity application:

• Absence of bacterial backbone sequences — minicircles carry only the therapeutic expression cassette, reducing immunogenic load and epigenetic silencing
• No genomic integration — minicircles remain episomal, eliminating insertional mutagenesis risk
• Improved safety profile for repeat administration — critical for a therapy designed to be re-administered annually as levels decline
• No pre-existing immune responses — unlike AAV serotypes, minicircle DNA does not trigger neutralizing antibodies that would limit efficacy on re-dosing
• Regulatory flexibility — minicircle-based non-integrating gene therapy operates outside the US regulatory framework, accessible to patients now

The trade-off is expression duration: minicircle constructs yield approximately 8–12 months of sustained expression, compared to potentially longer durations with AAV. For a longevity application where annual re-dosing is clinically acceptable — and arguably preferable for dose titration — this is a favorable profile.

Gene Construct

Construct: miniVec-CMV-hKl[NM-004795-4]-SMAR-SV40pA

The minicircle vector encodes the human secreted Klotho isoform (s-KL) under control of a CMV promoter, enabling strong transient expression. The scaffold/matrix attachment region (SMAR) element enhances nuclear retention and prolongs episomal persistence. SV40 polyadenylation signal ensures efficient transcript termination.

Administration Protocol

Dose and Delivery

Dose: 100 µg minicircle DNA per administration

Delivery method: Lipofectamine nanoparticle encapsulation

Injection medium: 1 mL Opti-MEM

Injection site: Subcutaneous adipose tissue

Adipocytes serve as temporary biological factories, producing circulating Klotho protein that enters the systemic bloodstream and acts as a hormone across multiple organ systems.

Injection Site Reaction

Typical response: mild inflammation, localized induration, and complete resolution within 4–5 days. No systemic adverse events have been observed across the patient series reported here.

Onset of Physiological Effects

Patients typically report subjective cognitive and physical effects within 7–10 days of administration, consistent with the expected timeframe for transgene expression, protein synthesis, and measurable plasma elevation.

Plasma Klotho Measurement

Plasma Klotho concentrations are measured by ELISA. Commercial kits are sourced from Japanese manufacturers with established specificity for the soluble Klotho isoform (s-KL).

Post-therapy response: following minicircle administration, plasma Klotho increases sharply and elevated levels persist for several months. Estimated functional half-life of expression: approximately 8 months, with individual variation based on metabolic rate, body composition, and baseline renal function.

Cognitive Function Observations

No significant effect was observed in young individuals without cognitive complaints, or in patients with advanced dementia or late-stage Alzheimer’s disease. Clinically meaningful improvements were observed in patients over 55 with mild-to-moderate age-related cognitive complaints.

Reported improvements include: enhanced memory recall, improved focus and mental clarity, faster cognitive recovery after sustained mental effort, and improved subjective energy.

Mechanistic Basis

These observations are consistent with Klotho’s known neurological mechanisms: enhanced hippocampal synaptic plasticity, increased BDNF signaling, improved GRIN2B (NMDA receptor) function, and reduction of neuroinflammation. The Roig-Soriano et al. 2025 study confirmed increased hippocampal neurogenesis and improved microglial phagocytic activity — the brain’s cleanup function — in Klotho-treated mice at 24 months (approximately equivalent to 70 human years).

Cognitive Monitoring — Updated Protocol

Standard cognitive screening tools such as the Montreal Cognitive Assessment (MoCA) have insufficient sensitivity for high-functioning individuals — ceiling effects mask real-world cognitive changes in this population.

Our current monitoring protocol incorporates:

• QEEG (quantitative EEG) — coming soon; will provide objective neurophysiological data independent of patient-reported outcomes
• Longitudinal tracking integrating the Cognitive Failures Questionnaire (CFQ) and Brain Health Assessment (BHA) tools
• Sleep quality and autonomic regulation measurements (HRV-based)
• Subjective cognitive recovery speed after mental load — identified as the most sensitive self-reported indicator in our patient population

Kidney Function Observations

Klotho is primarily produced in the distal convoluted tubule of the kidney. The relationship between Klotho and renal function is bidirectional: declining kidney function reduces Klotho production, and low Klotho accelerates further renal deterioration. Gene therapy that restores circulating Klotho can therefore break this cycle by improving renal resilience, reducing tubular inflammation, and improving glomerular filtration markers.

Clinical Context

Across our patient series, eGFR improvements following Klotho gene therapy have been the most consistently documented objective finding. In patients with pre-existing renal impairment, improvements have ranged from modest (5–10 mL/min/1.73m²) to dramatic, as illustrated in Case 1 below.

Biomarker Data — Clinical Cases

The following cases represent a subset of patients for whom longitudinal biomarker data is available. Many patients do not return for follow-up testing — they report satisfactory outcomes and seek retreatment when they perceive benefit declining. This selection bias should be noted when interpreting trends.

Renal function improvements (eGFR, creatinine) have remained stable at one-year follow-up in cases where longitudinal data is available. Immune and inflammatory markers show a tendency to return toward baseline at approximately 12 months, consistent with declining Klotho levels as expression duration expires — supporting the case for annual re-dosing.

Case 1 — Post-Radiation Renal Damage

A patient with severe renal compromise following pelvic radiation therapy. Trajectory: initial renal impairment → partial improvement during concurrent stem cell therapy → acute severe deterioration following UTI and kidney infection → rapid recovery following Klotho minicircle therapy. Emergency physicians monitoring the patient were unable to account for the speed of recovery.

Notable: eGFR progression from 9 → 32 following Klotho therapy after near-complete renal failure. Ferritin normalization and lymphocyte recovery are consistent with a marked anti-inflammatory shift.

Case 2 — D

Male patient with elevated PSA and baseline mild renal impairment. Klotho gene therapy administered January 2025; two-year follow-up available.

Notable: PSA declined from 5.81 to 2.69 over 12 months post-Klotho; AFP normalized from 4.05 to 0.50. eGFR improved from 59 to 72. These trends are consistent with Klotho’s documented tumor suppressor activity — see companion article: Klotho: The Anti-Aging Protein That Also Fights Cancer.

Case 3 — S

Male patient with elevated PSA and borderline creatinine. Klotho administered August 2025; six-month follow-up.

Notable: PSA reduction from 8.09 to 4.90; creatinine normalization; eGFR improvement from 62 to 88 — one of the most striking renal recovery trajectories in our series.

Case 4 — A

Male patient with elevated PSA and mild renal impairment. Klotho administered December 2024; six-month follow-up.

Notable: Modest but consistent improvements across renal and PSA markers at 5 months. Longer follow-up anticipated.

Case 5 — M

Patient with borderline renal function and elevated PSA. Klotho administered October 2025; four-month follow-up.

Notable: eGFR 67 → 90 over four months; hemoglobin normalization; creatinine reduction from 1.10 to 0.76. PSA showed a slight increase — ongoing monitoring warranted.

A Note on PSA Trends

Across four of the five cases presented, PSA showed declining trends following Klotho gene therapy. PSA is commonly used as a prostate cancer surveillance marker, and its reduction is clinically significant in male patients with elevated baseline values. These observations are consistent with Klotho’s documented epigenetic tumor suppressor activity — Klotho expression is silenced in multiple cancer types, and its restoration has been shown to reduce proliferative signaling in prostate, breast, and other malignancies.

For a detailed review of the science, see our companion article: Klotho: The Anti-Aging Protein That Also Fights Cancer (BlastLongevity.com/klotho-the-anti-aging-protein-that-also-fights-cancer/).

Case 5 showed a slight PSA increase at four months — illustrating that these trends are not universal and that continued monitoring is appropriate. We do not represent these observations as evidence of anti-cancer efficacy; they are biomarker trends requiring longitudinal confirmation.

Synergy: Klotho Gene Therapy with PSC Therapy and Exosomes

Klotho gene therapy at Blast Institute is frequently administered as part of a broader regenerative protocol that includes pluripotent stem cell (PSC) therapy and PSC-derived exosomes. The Case 1 trajectory above illustrates the sequential layering: stem cell therapy initiated the renal recovery process; Klotho gene therapy dramatically accelerated and consolidated it.

The mechanistic basis for this synergy is meaningful:

• Klotho establishes the anti-aging hormonal environment — reducing systemic inflammation, oxidative burden, and senescent cell signaling — in which PSC-derived regenerative processes can operate more effectively
• PSCs contribute paracrine regenerative signaling through their in-vivo expressed exosomal output, which is adaptive and contextually responsive to the tissue environment
• Lab-harvested PSC-derived exosomes deliver concentrated foundational regenerative cargo — growth factors, miRNAs, signaling proteins — that complement and amplify Klotho’s systemic effects
• Together, the three modalities address cellular aging at a depth and durability that no single agent achieves independently

Limitations

These observations represent preliminary clinical data and should be interpreted with appropriate caution. Current limitations include:

• Small sample size — not all patients are available or willing to undergo follow-up testing; many return for retreatment based on subjective outcomes without formal biomarker assessment
• Observational design — no randomized control group; multiple concurrent interventions in most cases make attribution to Klotho alone uncertain
• Selection bias — the cases presented are those for whom longitudinal data was available, which may overrepresent favorable responders
• Variable follow-up duration — ranging from 4 months (Case 5) to 15 months (Case 2), limiting longitudinal conclusions
• Concurrent interventions — several patients received PSC therapy, exosomes, or other modalities alongside or preceding Klotho; independent effect attribution requires controlled comparison

We are currently expanding longitudinal data collection to generate biomarker datasets, cognitive performance monitoring, renal function charts, and Klotho pharmacokinetic curves. Future reports will include expanded statistical analysis, QEEG data, and graphical representation of individual patient trajectories.

All participants provided informed consent. All procedures were performed in a clinical setting under physician supervision.

---

Key References

• Roig-Soriano J, et al. Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience. Molecular Therapy. 2025;33(4):1449. DOI: 10.1016/j.ymthe.2025.02.030
• Kuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.
• Kurosu H, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309(5742):1829–1833.
• Dubal DB, et al. Life extension factor klotho enhances cognition. Cell Reports. 2014;7(4):1065–1076.
• Abraham CR, Li A. Aging-suppressor Klotho: Prospects in diagnostics and therapeutics. Ageing Research Reviews. 2022;82:101766.
• Liu H, et al. Klotho Protein: A Multifaceted Guardian of Healthy Aging and Its Therapeutic Potential. International Journal of Nanomedicine. 2025;20:7251–7270.
• Ortega MA, Boaru DL, et al. Alpha-Klotho as a tumor suppressor: mechanisms and clinical implications across cancer types. Genes. 2025;16:128.